Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis
- PMID: 24356717
- DOI: 10.18926/AMO/52006
Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis
Abstract
Autophagy is a catabolic process that produces energy through lysosomal degradation of intracellular organelles. Autophagy functions as a cytoprotective factor under physiological conditions such as nutrient deprivation, hypoxia, and interruption of growth factors. On the other hand, infection with pathogenic viruses and bacteria also induces autophagy in infected cells. Oncolytic virotherapy with replication-competent viruses is thus a promising strategy to induce tumor-specific cell death. Oncolytic adenoviruses induce autophagy and subsequently contribute to cell death rather than cell survival in tumor cells. We previously developed a telomerase-specific replication-competent oncolytic adenovirus, OBP-301, which induces cell lysis in tumor cells with telomerase activities. OBP-301-mediated cytopathic activity is significantly associated with induction of autophagy biomarkers. In this review, we focus on the tumor-suppressive role and molecular basis of autophagic machinery induced by oncolytic adenoviruses. Addition of tumor-specific promoters and modification of the fiber knob of adenoviruses supports the oncolytic adenovirus-mediated autophagic cell death. Autophagy is cooperatively regulated by the E1-dependent activation pathway, E4-dependent inhibitory pathway, and microRNA-dependent fine-tuning. Thus, future exploration of the functional role and molecular mechanisms underlying oncolytic adenovirus-induced autophagy would provide novel insights and improve the therapeutic potential of oncolytic adenoviruses.
Similar articles
-
Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer.Int J Mol Sci. 2017 Jul 10;18(7):1479. doi: 10.3390/ijms18071479. Int J Mol Sci. 2017. PMID: 28698504 Free PMC article. Review.
-
Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis.Int J Cancer. 2012 Dec 15;131(12):2939-50. doi: 10.1002/ijc.27589. Epub 2012 Apr 30. Int J Cancer. 2012. PMID: 22492316
-
Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.Int J Mol Med. 2013 Feb;31(2):377-85. doi: 10.3892/ijmm.2012.1197. Epub 2012 Nov 29. Int J Mol Med. 2013. PMID: 23229955
-
Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.Mol Cancer Ther. 2013 Mar;12(3):314-25. doi: 10.1158/1535-7163.MCT-12-0869. Epub 2013 Jan 11. Mol Cancer Ther. 2013. PMID: 23315976
-
Oncolytic adenoviruses for the treatment of brain tumors.Curr Opin Mol Ther. 2010 Oct;12(5):530-7. Curr Opin Mol Ther. 2010. PMID: 20886384 Review.
Cited by
-
Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer.Int J Mol Sci. 2017 Jul 10;18(7):1479. doi: 10.3390/ijms18071479. Int J Mol Sci. 2017. PMID: 28698504 Free PMC article. Review.
-
Chaperone-Mediated Autophagy in the Liver: Good or Bad?Cells. 2019 Oct 24;8(11):1308. doi: 10.3390/cells8111308. Cells. 2019. PMID: 31652893 Free PMC article. Review.
-
Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.Oncolytic Virother. 2017 Nov 8;6:39-49. doi: 10.2147/OV.S145262. eCollection 2017. Oncolytic Virother. 2017. PMID: 29184854 Free PMC article. Review.
-
Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer.Mol Ther Oncolytics. 2022 Sep 13;27:3-13. doi: 10.1016/j.omto.2022.09.003. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36212775 Free PMC article.
-
Oncolytic adenoviruses: A thorny path to glioma cure.Genes Dis. 2014 Dec;1(2):214-226. doi: 10.1016/j.gendis.2014.09.009. Genes Dis. 2014. PMID: 25685829 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources